SEBIO 2006 Presenter and Sponsor Profiles.

ATLANTA & CHARLOTTESVILLE, Va. -- Southeastern BIO Investor Forum 2006 (SEBIO 2006) takes place November 8-10, 2006 at the InterContinental Buckhead Hotel in Atlanta, Ga. For in-depth information about the event, please visit http://www.sebio.org/investorforum/2006/index.asp.

Below are profiles from SEBIO 2006 presenters and sponsors. Breaking news releases are available at http://www.tradeshownews.com.

Business Wire is the official news wire service for SEBIO 2006.

Company: AerovectRx, Corporation

Ticker Symbol & Exchange: Private

Media Contact: Bill Wells

Investor Relations Contact: Matthew Kim

Phone: [phone]

E-mail: [e-mail]

Web: http://www.aerovectrx.com

AerovectRx Corporation is an aerosol therapeutic company providing customized drug delivery solutions using the lung as the gateway for better health. Our FDA-cleared AeroCell[TM] disposable drug cartridge is unique to the industry and is designed to improve patient compliance and eliminate cross contamination. Products under development by AerovectRx are designed to deliver a wide variety of therapies through multiple-use mass immunization as well as personal-use nebulizers. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and anti-viral drugs. For more information, visit http://www.aerovectrx.com.

Company: Altor Bioscience Corporation

Media Contact: Peter Rhode

Investor Relations Contact: Peter Rhode

Phone: [phone]

E-mail: [e-mail]

Web: http://www.altorbioscience.com

Altor BioScience Corporation is a venture-backed biopharmaceutical company dedicated to maximizing shareholder value through the discovery, development and commercialization of targeted immunotherapeutics for the treatment of cancer, viral infections, and autoimmune diseases. These drugs are created by utilizing Altor's integrated proprietary technologies for soluble T cell receptor (STAR-TM) and major histocompatibility complex molecules. Altor is employing these disease targeting delivery platforms to improve the safety and efficacy of existing therapeutics. Altor has diligently secured its leadership position with an experience management team, strong intellectual property and promising lead products at the clinical and late preclinical stages.

Company: BioDtech, Inc.

Media Contact: [e-mail]

Investor Relations Contact: [e-mail]

Phone: [phone]

E-mail: [e-mail]

Web: http://www.biodtechinc.com

BioDtech, Inc. (BDTI) was formed in September 2003 to accelerate the development of technologically advanced products geared toward the detection, neutralization and removal of biological toxins. Endotoxin is one such toxin produced by gram-negative bacteria and is a potent stimulator of the immune system. Sepsis, an over stimulation of the immune system, afflicts 750,000 people resulting in 210,000 deaths in the United States alone with an annual cost estimated at $16.7 billion. Sepsis mortality is estimated at 9.3% of all deaths in the US. BDTI has conducted extensive market research in the existing endotoxin marketplace. We discovered an opportunity existed to develop new technology based on existing patented research (U.S Patent No. 6,719,973). BDTI has signed a License Agreement with the National University of Singapore (NUS) for the exclusive worldwide licensing rights.

Company: IntraTherm, LLC 

Media Contact: Jerry Mraz

Investor Relations Contact: Jerry Mraz

Phone: [phone]

E-mail: [e-mail]

Web: http://www.IntraTherm.com

IntraTherm, LLC is focused on continuous improvement of the medical device industry through the introduction of innovative processes and products that aids surgeons and patients in their fight against cancer. Our product, CITT, is designed to complement surgery by "sterilizing" the site of surgical resection via a controllable and predictable thermal ablation device, with less than minimal short term, and without long term side effects. IntraTherm is the collaboration of medical research professionals and leading micro-technology industry specialists dedicated to bringing new technological advancements in healthcare to the marketplace. IntraTherm, a privately held Limited Liability Company organized in Arkansas since 2002.

Company: Nanotherapeutics, Inc.

Media Contact: Mento Soponis

Phone: [phone]

E-mail: [e-mail]

Web: http://www.nanotherapeutics.com

Nanotherapeutics, Inc. is an emerging technology-based biopharmaceutical company providing drug delivery solutions for the development of novel pharmaceuticals, and to support product lifecycle extensions for the pharmaceutical industry. Nanotherapeutics has a growing intellectual property positions in the areas of nano-scale powder processing, drug delivery and thin-film deposition. Three proprietary nanotechnologies provide the Company with the platform to create novel delivery solutions for oral, inhaled and injectible administration.

Company: NanoVici, Inc.

Investor Relations Contact: Dan Ciprari, CEO 

Phone: [phone]

E-mail: [e-mail]

Web: http://www.nanovici.com

NanoVici, Inc. is an Atlanta-based biopharmaceutical company formed to commercialize targeted nanotherapeutics licensed from Emory University and Georgia Tech. Our lead therapeutic candidate, NV-111, targets folic acid receptive cancers, representing 28% of all solid tumor cancers and a $10 billion worldwide market. In university lab tests repeated with very consistent results, NV-111 completely destroys cancer tumors with folate receptors. Our Chief Scientific Officer, Dr. Shuming Nie, is the Principal Investigator for the Emory / Georgia Tech Center of Cancer Nanotechnology Excellence (CCNE), recipient of a $20 million grant from the National Cancer Institute to develop nanotherapeutics for cancer.

Company: Phase BioScience, Inc.

Media Contact: Amy DelaCourt

Investor Relations Contact: Gabriel Cipau

Phone: [phone]

E-mail: [e-mail]

Web: http://www.phasebio.com

PhaseBio is an RTP North Carolina-based company, revolutionizing the development of biotherapeutics through innovative technology licensed from Duke University. By focusing initially on medical markets with significant unmet need, such as certain forms of cancer, PhaseBio is developing a portfolio of products which deliver existing therapeutic agents with greater efficacy and lower side effects. PhaseBio also offers services which provide for improved delivery and purification for therapeutic proteins and peptides. The company has on-going collaborations with several biopharmaceutical companies. Several in vitro studies have been performed and one in vivo to evaluate ELPs alone, and an ELP-doxorubicin conjugate in tumors.

Company: Precision BioSciences

Phone: [phone]

E-mail: [e-mail]

Web: http://www.precisionbiosciences.com

Precision BioSciences is focused on creating real solutions to genetic problems by harnessing the power of the world's most precise DNA editing technology. Precision BioSciences' proprietary Directed Nuclease Editor is the first and only to offer the customizability, specificity, efficiency, and safety required for extremely accurate in vitro and in vivo targeting and editing of virtually any gene in any genome. The Directed Nuclease Editor is a true technology platform and has applications across nearly every facet of biotechnology, including human health, agriculture, research, and defense.

Company: RFS Pharma, LLC

Media Contact: Christopher Thurman

Investor Relations Contact: Dr. Raymond F. Schinazi

Phone: [phone]

E-mail: [e-mail]

Web: http://www.rfspharma.com

RFS Pharma, LLC, was founded in September 2004 in Tucker, Georgia by Dr. Raymond F. Schinazi and is committed to the research and development of novel, patentable, proprietary drugs, primarily nucleosides, for the treatment of life-threatening diseases, such as HIV-1, hepatitis viruses, and emerging viruses. Our lead patented product candidate, amdoxovir[R] (DAPD, AMDX), is in late Phase 2 studies for the treatment of HIV-1 infections under an US IND. It is well tolerated and very effective at decreasing viral load in HIV infected individuals, including those with extensive nucleoside reverse transcriptase inhibitor mutations. Other nucleoside analogs are in late preclinical development. Our 25,000 sq. ft. research facility houses state-of-the-art drug discovery, process chemistry, pharmacology, biochemistry, toxicology and virology laboratories as well as administrative offices.

Company: ViewRay

Media Contact: Russell Donda

Investor Relations Contact: Russell Donda

Phone: [phone]

E-mail: [e-mail]

Web: http://www.viewray.com

Nearly 75% of the cancer patients alive today will receive radiation therapy, a well known form of treatment. However, radiation therapy has a tremendous shortcoming that limits its effectiveness: Radiation oncologists cannot precisely tell where the radiation is going in a patient's body during therapy treatments. The ViewRay technology promises to become the world's first radiation therapy device to allow real-time volumetric MRI simultaneous with beam-on radiation delivery. For the first time in the history of radiation therapy, the treating physician will know precisely where the dose is going and if it's hitting the intended target.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email [e-mail].